An Open-label Study of ALPN-202 Combined With PD-1 Inhibition in Subjects With Advanced Malignancies (NEON-2)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Davoceticept (Primary) ; Pembrolizumab (Primary)
Indications Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions
Acronyms NEON-2
Sponsors Alpine Immune Sciences

02 Jun 2023 Status changed from active, no longer recruiting to discontinued.
08 Nov 2022 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2022.
24 Oct 2022 According to an Alpine Immune Sciences media release, the company has voluntarily terminated enrollment in the NEON-1 and NEON-2 trials. The decision to terminate enrollment in the davoceticept studies was made in the interest of patient safety after the Company was notified of a second death in the NEON-2 study, attributed to cardiogenic shock.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com